Israeli Multi Ethnic Centenarian Project
IMECP
Detection of Epigenome Variation Associated With Longevity Among the Multi Ethnic Centenarian Population in Israel
1 other identifier
observational
124
1 country
1
Brief Summary
This study will systematically assess epigenome methylation changes in participants of the Israel multi-ethnic centenarian study cohort, which includes citizens of Israel aged 95 years and older, compared to their offspring and younger controls.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
January 10, 2017
CompletedFirst Posted
Study publicly available on registry
May 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedApril 4, 2023
April 1, 2023
7 years
January 10, 2017
April 2, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Frequency of alleles in genes across the genome
Variations of frequency of alleles in study groups using dedicated software for genomic analysis.
6 months
Study Arms (2)
Older Cohort
Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
Younger Controls
Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
Eligibility Criteria
Subjects aged 95 years and older will form the study cohort. Control group will comprise children of the older subjects and age-matched controls.
You may qualify if:
- Aged 95 years and older.
- Provide verbal consent for participation in the study.
- Cognitively able to provide consent and answer a structured questionnaire.
You may not qualify if:
- Not able to provide consent for participation in the study.
- Impaired consciousness.
- Unable to communicate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rambam Health Care Campuslead
- Israel Science Foundationcollaborator
Study Sites (1)
Rambam Health Care Campus
Haifa, North, 3109601, Israel
Related Publications (3)
Brooks-Wilson AR. Genetics of healthy aging and longevity. Hum Genet. 2013 Dec;132(12):1323-38. doi: 10.1007/s00439-013-1342-z. Epub 2013 Aug 8.
PMID: 23925498BACKGROUNDEvert J, Lawler E, Bogan H, Perls T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci. 2003 Mar;58(3):232-7. doi: 10.1093/gerona/58.3.m232.
PMID: 12634289BACKGROUNDWojdacz TK, Hansen LL. Techniques used in studies of age-related DNA methylation changes. Ann N Y Acad Sci. 2006 May;1067:479-87. doi: 10.1196/annals.1354.069.
PMID: 16804030BACKGROUND
Biospecimen
Three 10 ml blood samples will be drawn into vacutainer tubes (Yellow top with anticoagulant; speckled top without anticoagulant). Blood samples will be analyzed for the levels of hemoglobin, hematocrit, white blood cell counts, and levels of glucose, insulin, albumin, inflammatory markers, and plasma lipids. CD34+Lin- cells will be isolated from the peripheral blood specimen using immuno-magnetic separation technique, followed by cell sorter. Mononuclear cells are separated by Ficoll-Paque density gradient, and CD34+ cells obtained by positive immuno-magnetic bead selection, using Macs columns (Miltenyi Biotech). The purified cells are then subjected to a cell sorter following immunostaining. The isolated cells will be cryopreserved in 10% DMSO by controlled rate freezing.
Study Officials
- PRINCIPAL INVESTIGATOR
Tzvi Dwolatzky, MD
Rambam Health Care Campus
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of Geriatric Medicine
Study Record Dates
First Submitted
January 10, 2017
First Posted
May 30, 2018
Study Start
January 1, 2016
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
April 4, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share
Individual Participant Data (IPD) will not be shared